Sertraline: A review of its therapeutic use in post-traumatic stress disorder

CNS Drugs

Volumn 14, Issue 5, 2000, Pages 391-407

  Comer, A M ^a   Figgitt, D P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; HUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW;

EID: 0033724699     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014050-00006     Document Type: Review

References (109)

1. Post-traumatic stress disorder: Pathophysiological aspects and pharmacological approaches to treatment
2. Posttraumatic stress disorder: Epidemiology and health-related considerations
3. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety
4. Posttraumatic stress disorder in the National Comorbidity Survey
5. Suicide and guilt as manifestations of PTSD in Vietnam combat veterans
6. Systematic review and guide to selection of selective serotonin reuptake inhibitors
7. The SSRIs: Advantages, disadvantages and differences
8. Drug choice in depression: Selective serotonin reuptake inhibitors or tricyclic antidepressants?
9. Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder
10. Sertraline: A pharmacoeconomic evaluation of its use in depression
11. Sertraline: An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder
12. Current concepts in the treatment of panic disorder
13. A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms
14. Discussion: Treatment of prolonged posttraumatic stress disorder-learning from experience
15. Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event
16. Posttraumatic stress disorder in an urban population of young adults: Risk fators for chronicity
17. Uncontrollability and unpredictability in post-traumatic stress disorder: An animal model
18. Auditory startle response in trauma survivors with posttraumatic stress disorder: A prospective study
19. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy?
20. Biology of posttraumatic stress disorder
21. Post-traumatic stress disorder and serotonin: New directions for research and treatment
22. The psychobiology of posttraumatic stress disorder
23. Noradrenergic and serotonergic function in posttraumatic stress disorder
24. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
25. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
26. Sertraline: A new antidepressant
27. Interactions of selective serotonin reuptake inhibitors with subtypes of o receptors in rat brain
28. Differential pharmacology of newer antidepressants
29. The behavioural toxicity of antidepressants: Effects on cognition and sexual function
30. Psychopharmacological effects of sertraline in normal healthy volunteers
31. The effects of sertraline on psychomotor performance in elderly volunteers
32. Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects
33. Acute effects of sertraline, amitriptyline and placebo on the psychomotor performance of healthy subjects over 50 years oaf age
34. Selective serotonin reuptake inhibitors and CNS drug interactions: A critical review of the evidence
35. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
36. Influence of liver cirrhosis on sertraline pharmacokinetics
37. Safety and pharmacokinetics of sertraline in healthy young males
38. Clinical implications of the pharmacology of sertraline
39. Identification of human cytochrome P450 isoforms involved in sertraline Ndemethylation
40. Evidence for involvement of polymorphic CYP2Cl9 and 2C9 in the N-demethylation of sertraline in human liver microsomes
41. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
42. Breastfeeding and sertraline: A 24-hour analysis
43. Sertraline and desmethylsertraline in human breast milk and nursing infants
44. Distribution and excretion of sertraline and N-desmethylsertraline in human milk
45. Serum sertraline and N-desmethylsertraline levels in breast-feeding ntother-infant pairs
46. Sertraline and norsertraline levels in three breastfeed infants
47. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series
48. Sertraline: Chronopharmacokinetics and the effect of coadministration with food
49. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers
50. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline
51. CYP2D6 inhibition in patients treated with sertraline
52. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation
53. Effect of sertraline on protein binding of warfarin
54. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo
55. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers
56. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin
57. Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine
58. Clonazepam (Klonopin®) and sertraline (Zoloft®): Absence of drug interaction in a multiple dose stuffy
59. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo
60. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers
61. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
62. Effect of sertraline on plasma nortriptyline levels in depressed elderly
63. Coadministration of short-term zolpidem with sertraline in healthy women
64. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide
65. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings
66. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers
67. The effect of sertraline on the pharmacokinetics of desipramine and imipramine
68. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
69. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo
70. Co-administration of sertraline and haloperidol
71. Treatment of posttraumatic stress disorder
72. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial
73. Zoloft (sertraline hydrochloride). Proposed indication treatment of PTSD
74. Double-blind comparison of sertraline and placebo in patients with posttraumatic stress disorder
75. Sertraline for PTSD: NDA 19-839, statistical review
76. A placebo-controlled pilot study of sertraline in PTSD
77. Effects of sertraline and placebo in women with PTSD
78. Effects of sertraline and placebo in men with PTSD
79. Double-blind, randomized, 28-week continuation study of sertraline and placebo in PTSD
80. Results of a 24-week extension study of sertraline in PTSD
81. Sertraline efficacy in depressed combat veterans with post-traumatic stress disorder
82. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence
83. Sertraline in the treatment of rape victims with posttraumatic stress disorder
84. Sertralinc in PTSD
85. Two multicenter trials evaluating sertraline and placebo for the treatment of PTSD
86. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients
87. Sexual dysfunction induced by serotonin reuptake antidepressants
88. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
89. Sertraline overdose
90. A controlled trial of phenelzine in posttraumatic stress disorder
91. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder
92. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine
93. A double-blind, randomized, placebo-controlled, multicenter study of brofaromine in the treatment of post-traumatic stress disorder
94. Pharmacotherapy of posttraumatic stress disorder with a novel psychotropic
95. A controlled trial of desipramine in 18 men with posttraumatic stress disorder
96. Treatment of posttraumatic stress disorder with amitriptyline and placebo
97. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment
98. Fluoxetine in post-traumatic stress disorder: Randomised, double-blind study
99. Fluoxetine in posttraumatic stress disorder
100. Treatment for posttraumatics stress disorder
101. FDA clears Zoloft for post-trauma
102. Open pro-spective trial of fluoxetine for posttraumatic stress disorder
103. Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder
104. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder
105. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder